Oncology status update: Difference between revisions
Jump to navigation
Jump to search
Hudakarman (talk | contribs) |
Hudakarman (talk | contribs) |
||
| Line 668: | Line 668: | ||
|- | |- | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Myelofibrosis | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| Line 677: | Line 677: | ||
|- | |- | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Nodal marginal zone lymphoma | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| Line 686: | Line 686: | ||
|- | |- | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Non-Hodgkin lymphoma (LP) | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| Line 695: | Line 695: | ||
|- | |- | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Polycythemia vera | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| Line 704: | Line 704: | ||
|- | |- | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Primary effusion lymphoma | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| Line 713: | Line 713: | ||
|- | |- | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Primary mediastinal large B-cell lymphoma (SP) | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| Line 722: | Line 722: | ||
|- | |- | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Prolymphocytic leukemia (LP) | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| Line 731: | Line 731: | ||
|- | |- | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |T cell prolymphocytic leukemia (SP) | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| Line 740: | Line 740: | ||
|- | |- | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |B cell prolymphocytic leukemia (SP) | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| Line 749: | Line 749: | ||
|- | |- | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Splenic marginal zone lymphoma | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| Line 758: | Line 758: | ||
|- | |- | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Enteropathy-associated T-cell lymphoma | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| Line 767: | Line 767: | ||
|- | |- | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |T-cell lymphoma (LP) | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| Line 776: | Line 776: | ||
|- | |- | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Waldenström's macroglobulinemia | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| Line 785: | Line 785: | ||
|- | |- | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Hepatosplenic T cell lymphoma | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
Revision as of 05:34, 3 July 2020
System leader: Farima Kahe, M.D.
List of Chapters Requiring Content
| Category | Chapters that need content | Assignment Status | Scholar's name | Coach name | Completion Status | Review status | Reviewer name |
|---|---|---|---|---|---|---|---|
| Oncology | |||||||
In progress chapters
| Category | Chapters that need content | Assignment Status | Scholar's name | Coach name | Completion Status | Review status | Reviewer name |
|---|---|---|---|---|---|---|---|
| Oncology | |||||||
Completed chapters
| Category | Chapters that need content | Assignment Status | Scholar's name | Coach name | Completion Status | Review status | Reviewer name |
|---|---|---|---|---|---|---|---|
| Oncology | Acute lymphoblastic leukemia | ||||||
| Acute myeloid leukemia | |||||||
| Acute promyelocytic leukemia | |||||||
| Adult T-cell leukemia | |||||||
| Anaplastic large cell lymphoma | |||||||
| Burkitt's lymphoma | |||||||
| Chronic lymphocytic leukemia | |||||||
| Chronic myelogenous leukemia | |||||||
| Chronic neutrophilic leukemia | |||||||
| Diffuse large B cell lymphoma | |||||||
| Follicular lymphoma | |||||||
| Hairy cell leukemia | |||||||
| Hodgkin's lymphoma | |||||||
| Leukemia (LP) | |||||||
| Leukocytosis (SP) | |||||||
| Hemophilia | |||||||
| Lymphadenopathy | |||||||
| Lymphangioma | |||||||
| Lymphangiomyomatosis (SP) | |||||||
| Lymphangiosarcoma (SP) | |||||||
| Lymphoma (LP) | |||||||
| Lymphomatoid granulomatosis | |||||||
| Mast cell leukemia | |||||||
| Mast cell tumor | |||||||
| Multiple myeloma | |||||||
| Myelodysplastic syndrome | |||||||
| Myelofibrosis | |||||||
| Nodal marginal zone lymphoma | |||||||
| Non-Hodgkin lymphoma (LP) | |||||||
| Polycythemia vera | |||||||
| Primary effusion lymphoma | |||||||
| Primary mediastinal large B-cell lymphoma (SP) | |||||||
| Prolymphocytic leukemia (LP) | |||||||
| T cell prolymphocytic leukemia (SP) | |||||||
| B cell prolymphocytic leukemia (SP) | |||||||
| Splenic marginal zone lymphoma | |||||||
| Enteropathy-associated T-cell lymphoma | |||||||
| T-cell lymphoma (LP) | |||||||
| Waldenström's macroglobulinemia | |||||||
| Hepatosplenic T cell lymphoma | |||||||